StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) stock

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302535% above fair value
$403.60−9.66 (-2.34%)

Close on Nov 18, 2026Market cap $45.89BP/E 72.2Yield –

BeOne Medicines free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

BeOne Medicines's free cash flow for the twelve months ending Jun 30, 2026 was $1.33B, up 443.3% year over year. For fiscal 2025 it was $941.74M. The highest annual figure on record is $941.74M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$941.74M–
FY2024Dec 31, 2024-$633.29M–
FY2023Dec 31, 2023-$1.72B–
FY2022Dec 31, 2022-$1.82B–
FY2021Dec 31, 2021-$1.56B–
FY2020Dec 31, 2020-$1.40B–
FY2019Dec 31, 2019-$839.88M–
FY2018Dec 31, 2018-$618.00M–
FY2017Dec 31, 2017-$33.62M–
FY2016Dec 31, 2016-$113.02M–
FY2015Dec 31, 2015-$45.16M–
FY2014Dec 31, 2014-$9.35M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$435.34M+98.1%
Q1 FY2026Mar 31, 2026$160.55M–
Q4 FY2025Dec 31, 2025$379.83M–
Q3 FY2025Sep 30, 2025$354.47M+547.9%
Q2 FY2025Jun 30, 2025$219.77M–
Q1 FY2025Mar 31, 2025-$12.33M–
Q4 FY2024Dec 31, 2024-$17.32M–
Q3 FY2024Sep 30, 2024$54.71M–
Q2 FY2024Jun 30, 2024-$205.54M–
Q1 FY2024Mar 31, 2024-$465.15M–
Q4 FY2023Dec 31, 2023-$378.60M–
Q3 FY2023Sep 30, 2023-$236.03M–
Q2 FY2023Jun 30, 2023-$415.36M–
Q1 FY2023Mar 31, 2023-$689.36M–
Q4 FY2022Dec 31, 2022-$439.55M–
Q3 FY2022Sep 30, 2022-$670.56M–
Q2 FY2022Jun 30, 2022-$430.25M–
Q1 FY2022Mar 31, 2022-$281.69M-440.6%
Q4 FY2021Dec 31, 2021-$622.82M–
Q3 FY2021Sep 30, 2021-$562.76M–
Q2 FY2021Jun 30, 2021-$458.80M–
Q1 FY2021Mar 31, 2021$82.71M–
Q4 FY2020Dec 31, 2020-$367.02M–
Q3 FY2020Sep 30, 2020-$374.92M–
Q2 FY2020Jun 30, 2020-$295.55M–
Q1 FY2020Mar 31, 2020-$363.48M–
Q4 FY2019Dec 31, 2019-$282.65M–
Q3 FY2019Sep 30, 2019-$295.89M–
Q2 FY2019Jun 30, 2019-$67.55M–
Q1 FY2019Mar 31, 2019-$193.80M–
Q4 FY2018Dec 31, 2018-$217.15M-390.2%
Q3 FY2018Sep 30, 2018-$158.91M–
Q2 FY2018Jun 30, 2018-$127.75M–
Q1 FY2018Mar 31, 2018-$114.20M–
Q4 FY2017Dec 31, 2017$74.82M–
Q3 FY2017Sep 30, 2017-$11.96M–
Q2 FY2017Jun 30, 2017-$55.70M–
Q1 FY2017Mar 31, 2017-$40.78M–
Q4 FY2016Dec 31, 2016-$34.20M–
Q3 FY2016Sep 30, 2016-$30.96M–

More BeOne Medicines figures

See a number that looks wrong?